(Q46171591)

20 December 2017

title

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus (English)

1 reference

20 December 2017

0 references

0 references

B Komoroski

1

1 reference

20 December 2017

N Vachharajani

2

1 reference

20 December 2017

Y Feng

3

1 reference

20 December 2017

L Li

4

1 reference

20 December 2017

D Kornhauser

5

1 reference

20 December 2017

M Pfister

6

1 reference

20 December 2017

language of work or name

English

0 references

publication date

7 January 2009

1 reference

20 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

20 December 2017

volume

85

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

page(s)

513-519

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/clpt.2008.250

exact match

0 references

cites work

Islet beta cell failure in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Active sugar transport in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

TIMP-1 transgenic mice recover from diabetes induced by multiple low-dose streptozotocin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Long-term outcome of renal glucosuria type 0: the original patient and his natural history

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Candidal vulvovaginitis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

The auxiliary table for GFR estimation according to the MDRD formula

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.250

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.250

1 reference

20 December 2017

Dimensions Publication ID

0 references

1 reference

20 December 2017